论文部分内容阅读
目的 :临床验证马来酸曲美布汀 (舒丽启能 )治疗肠易激综合征 (IBS)的疗效及安全性。方法 :多中心开放基础上对照研究。选择IBS患者 6 4例 ,空白对照治疗 2周 ,15例临床症状缓解 ,49例进入舒丽启能治疗组 ,po ,2 0 0mg ,tid ,疗程 2周 ,观察腹痛、腹泻、排便异常、排便困难等症状变化。 结果 :舒丽启能对腹痛治疗有效率为91.8%。排便异常有效率为 89.8% ,腹泻有效率为 86 .6 % ,排便困难有效率为 81.8% ,总体评估总有效率为81.6 %。安全性研究未发现不良反应。结论 :舒丽启能治疗IBS是安全有效的。
Objective: To verify the efficacy and safety of trimebutine maleate (Shuli Qiteng) in the treatment of irritable bowel syndrome (IBS). Methods: A multicenter open-based, controlled study. Sixty-four patients with IBS and two weeks after blank control were selected. Fifteen patients were relieved of clinical symptoms, and 49 patients were treated with Shuliqi treatment group. Po, 200 mg, tid for 2 weeks. Abdominal pain, diarrhea, defecation and defecation were observed. Symptoms change. Results: Shu Liqi can effectively treat abdominal pain was 91.8%. The effective rate of defecation was 89.8%, the effective rate of diarrhea was 86.6%, the effective rate of defecation was 81.8% and the total effective rate was 81.6%. Safety studies found no adverse reactions. Conclusion: Shu Li Kai can treat IBS is safe and effective.